Curing a viral infection by targeting the host: The example of cyclophilin inhibitorsKai Lin, Philippe Gallay|Antiviral Research|2013Cited by 110
Nomenclature of HBV core protein-targeting antiviralsFabien Zoulim, Harry L.A. Janssen, Adam Zlotnick et al.|Nature Reviews Gastroenterology & Hepatology|2022Cited by 67
Correlation between NS5A Dimerization and Hepatitis C Virus ReplicationPrecious Lim, Philippe Gallay, Udayan Chatterji et al.|Journal of Biological Chemistry|2012Cited by 65
Multiple Mutations in Hepatitis C Virus NS5A Domain II Are Required To Confer a Significant Level of Resistance to AlisporivirJose A. Garcia-Rivera, Philippe Gallay, Sam Hopkins et al.|Antimicrobial Agents and Chemotherapy|2012Cited by 42
HCV NS5A and IRF9 compete for CypA bindingMichael Bobardt, Philippe Gallay, Sam Hopkins et al.|Journal of Hepatology|2012Cited by 28